Trial Profile
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms DAPA-HF
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Dec 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
- 01 Dec 2023 Results of a patient level pooled analysis assessing efficacy of Dapagliflozin according to Heart Rate from two clinical trials: DAPA-HF and DELIVER trials published in the Circulation: Heart Failure
- 13 Nov 2023 Results of pooled analysis from DAPA-HF and DELIVER assessing efficacy and safety outcomes by history of MI, presented at the American Heart Association Scientific Sessions 2023